Patient selection
for long-term cardiac monitoring

The LINQ™ family of insertable cardiac monitors (Reveal LINQ™ ICM and LINQ II™ ICM) helps you find answers for syncope, atrial fibrillation (AF), and cryptogenic stroke that short-term monitors might miss.

Back LINQ II and front Reveal LINQ insertable cardiac monitors shown vertically

Is 30 days long enough?

Here’s what you may be missing with a conventional 30-day monitor:

  • 74% of syncope diagnoses†1
  • AF diagnosis in 88% of cryptogenic stroke patients†2
  • 84.5% of patients at high risk of AF and stroke†3

†Based on Kaplan-Meier estimates.

Are your patients eligible for an insertable cardiac monitor (ICM)?

Find guidance on ICM patient selection for unexplained syncope, cryptogenic stroke, and difficult-to-detect AF, as well as for those who need long-term AF management.

Discover the LINQ family of ICMs.

When you need answers, trust the most accurate ICMs on the market.4-16

The proven LINQ family of ICMs delivers the data you need to make the right diagnosis for your patients.17

LINQ II and Reveal LINQ insertable cardiac monitors shown horizontally

Bring the Reveal LINQ ICM into your practice.

Interested in implanting the Reveal LINQ ICM in your practice? See how simple in-office implantation can be and contact us for a demo.

Reveal LINQ insertable cardiac monitor being held up in a hand

Learn more about challenging conditions.

Get more details about the conditions that may require long-term cardiac monitoring with the LINQ family of ICMs.

*

™Third-party brands are trademarks of their respective owners.

References

1

Rogers J, et al. Sensitivity of Conventional Monitoring Strategies to Diagnose Patients With Pause Arrhythmias Relative to Insertable Cardiac Monitors. Presented at AHA 2020.

2

Sanna T, Diener H, Passman RS, et al. Cryptogenic Stroke and Underlying Atrial Fibrillation. N Engl J Med. June 26, 2014; 370(26):2478-2486.

3

Reiffel JA, Verma A, Kowey PR, et al. Rhythm monitoring strategies in patients at high risk for atrial fibrillation and stroke: A comparative analysis from the REVEAL AF study. Am Heart J. January 2020;219:128-136.4.

4

Pürerfellner H, Sanders P, Sarkar S, et al. Adapting detection sensitivity based on evidence of irregular sinus arrhythmia to improve atrial fibrillation detection in insertable cardiac monitors. Europace. November 1, 2018;20(FI_3):f321-f328.

5

Nölker G, Mayer J, Boldt L, et al. Performance of an Implantable Cardiac Monitor to Detect Atrial Fibrillation: Results of the DETECT AF Study. J Cardiovasc Electrophysiol. December 2016;27(12):1403-1410.

6

Confirm Rx™* ICM K163407 FDA clearance letter. 2017.

7

Confirm Rx ICM K182981 FDA clearance letter. 2019.

8

Jot Dx™* ICM K212206 FDA clearance letter. 2021.

9

Monitoring Devices Merlin PCS Help Manual for SJM Confirm™*, Confirm Rx ICM, Jot Dx Manual. 2021. 

10

BIOTRONIK BioMonitor™* 2 technical manual. 2017.

11

BIOTRONIK BIOMONITOR III technical manual. 2020.

12

BIOTRONIK BIOMONITOR IIIm technical manual. 2020.

13

BIOTRONIK BIOMONITOR III. K190548 FDA clearance. 2019.

14

BIOTRONIK BIOMONITOR IIIm. K201865 FDA clearance. 2020.

15

Lux-Dx™* ICM K212206 FDA clearance letter. 2020.

16

Lux-Dx ICM User Manual. 2020.

17

ICM Publications. Medtronic data on file. 2021.